Prevalence of HBsAg among reproductive age couples in Chongqing: A population-based, cross-sectional study

PLoS One. 2021 Nov 15;16(11):e0260028. doi: 10.1371/journal.pone.0260028. eCollection 2021.

Abstract

Hepatitis B is a leading cause of death worldwide. Here, we performed a large, population-based, cross-sectional study in Chongqing, China from 2011 to 2016 to assess the prevalence of HBsAg among couples of reproductive age, to predict subsequent trends, and to provide evidence for the WHO goal of "the elimination of viral hepatitis as a public health threat by 2030". A total of 386,286 couples aged 20 to 49 years were enrolled in the study. Approximately 14.35% of couples were HBsAg positive, including 95.00% with discordant HBsAg positivity. HBsAg prevalence was higher in men than in women. Among different occupations, the two categories of "houseworker" (female 6.73%, male 9.99%) and "unemployed" (female 6.64%, male 9.94%) showed the highest HBsAg positivity. In different regions, the lowest prevalence appeared in southeastern Chongqing (female 4.87%, male 7.71%). In 2030, the HBsAg positivity rate is expected to be 2.79%, 7.27% and 5.13% in females, males, and the whole population, respectively. According to the trends, this rate would drop to less than 2% in 2034, 2078 and 2051. In conclusion, the HBsAg prevalence in Chongqing is still relatively high compared with that in other parts of western China, especially among reproductive-age men. HBsAg-positive couples should be taken as an important unit of care. Vaccination is necessary before pregnancy if no antibody is found. More attention should be given to people without stable jobs. HBsAg-positive rate will decrease perceptibly by 2030 and will reach the level of low in epidemic areas by 2050.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • China
  • Cross-Sectional Studies
  • Family Characteristics
  • Female
  • Hepatitis B / epidemiology*
  • Hepatitis B / immunology
  • Hepatitis B / prevention & control
  • Hepatitis B Antibodies / metabolism*
  • Hepatitis B Surface Antigens / immunology*
  • Hepatitis B virus / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Vaccination
  • Young Adult

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens

Grants and funding

QC received the fund from Science and Technology Bureau and Health Commission of Chongqing (2019MSXM053). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.